Licensing Opportunities The sale of FIBRINET assets to Royal Biologics points to licensing and co development as viable paths to re enter or expand the spine biologics market. Explore rights reacquisition or partnerships with distributors, leveraging FDA 510K clearance and CE Mark to negotiate terms and access global channels.

Clinical Value Proposition Position PRFM based intra procedural grafts as a value driver for spine fusion by engaging high volume centers. Build evidence through marketing studies and health economic analyses to demonstrate improved fusion rates, lower revision rates, and potential cost savings to payers and hospitals.

Global Regulatory Readiness With FDA clearance for broad orthopedic applications and a CE Mark for FIBRINET, pursue international market entry via distributors and localized clinical data. Develop regional regulatory plans, training programs, and evidence packages to support geography specific adoption.

Adjacent Market Expansion Beyond spine, the technology’s licensed use across orthopedic sports medicine, dermatology, wound care, cranial maxillofacial, periodontics, and veterinary markets offers cross selling opportunities. Leverage existing licensees and distribution networks to broaden the total addressable market and diversify revenue.

Strategic Partnerships Given modest revenue and a lean team, pursue strategic partnerships or minority investments with larger medtech players to accelerate go to market, fund marketing initiatives, and expand the sales footprint. Consider alliances with Cascade Medical licensees to leverage established commercialization channels.